Novavax' NanoFlu Influenza Vaccine Achieves All Primary Endpoints In Phase 3 Clinical Trial, Achieves Statistical Significance In Key Secondary Endpoint; Co. To Submit BLA Under Accelerated Approval Pathway
Benzinga Newsdesk